Related Experiment Videos
Dibenzoylmethane induces cell cycle deregulation in human prostate cancer cells
Kimberly M Jackson1, Marisela DeLeon, C Reynold Verret
1Winship Cancer Institute, Emory University School of Medicine, 1365-B Clifton Road, NE Rm. # 5204, Atlanta, GA 30322, USA.
Abstract:
Dibenzoylmethane (DBM), a minor beta-diketone constituent of licorice and sunscreens, has been shown to exhibit anti-neoplastic effects in chemically induced skin and mammary cancers in several animal models. To date, no mechanism for the growth inhibitory effects of DBM on prostate cancer cells has been proposed. In this study, we examined the effects of DBM on the growth and cell cycle kinetics of several human prostate carcinoma cell lines. Using an MTT cytotoxicity assay, IC50 values of 25-100 microM were observed following 72 h exposure to DBM. LNCaP, DU145, and PC-3 prostate carcinoma cell lines were particularly sensitive in comparison to the cells with the vehicle alone. Flow cytometric analyses showed deregulation of the cell cycle, which correlated with the observed cytostatic effects of DBM in prostate carcinoma cells. These data suggest a potential role for DBM in the prevention and treatment of prostate cancer.
Insights
Dibenzoylmethane (DBM) inhibits prostate cancer cell growth by disrupting the cell cycle. This beta-diketone shows potential for prostate cancer prevention and treatment.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Dibenzoylmethane (DBM), a beta-diketone found in licorice and sunscreens, exhibits anti-neoplastic properties in various cancer models.
- The mechanism of DBM's effect on prostate cancer cell growth remains unexplored.
Purpose of the Study:
- To investigate the impact of DBM on the growth and cell cycle kinetics of human prostate carcinoma cell lines.
- To determine the cytotoxic effects and effective concentrations of DBM against prostate cancer cells.
Main Methods:
- MTT cytotoxicity assay to determine IC50 values after 72-hour DBM exposure.
- Flow cytometric analysis to assess cell cycle deregulation in response to DBM treatment.
- Utilized LNCaP, DU145, and PC-3 human prostate carcinoma cell lines.
Main Results:
- DBM demonstrated significant cytotoxicity against prostate cancer cell lines, with IC50 values ranging from 25-100 microM.
- LNCaP, DU145, and PC-3 cell lines exhibited particular sensitivity to DBM compared to vehicle controls.
- Flow cytometry revealed cell cycle deregulation, correlating with the observed cytostatic effects of DBM.
Conclusions:
- DBM exhibits potent growth inhibitory effects on human prostate carcinoma cells.
- DBM-induced cell cycle deregulation is a key mechanism underlying its cytostatic activity.
- These findings suggest DBM holds promise as a therapeutic agent or preventative strategy for prostate cancer.